A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3030-3030 ◽  
Author(s):  
I. Brana ◽  
P. LoRusso ◽  
J. Baselga ◽  
E. I. Heath ◽  
A. Patnaik ◽  
...  
2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3004-3004 ◽  
Author(s):  
G. Edelman ◽  
C. Bedell ◽  
G. Shapiro ◽  
S. S. Pandya ◽  
E. L. Kwak ◽  
...  

2006 ◽  
Vol 24 (5) ◽  
pp. 413-421 ◽  
Author(s):  
Hervé Ghesquières ◽  
Sandrine Faivre ◽  
Latifa Djafari ◽  
Patricia Pautier ◽  
Catherine Lhommé ◽  
...  

2008 ◽  
Vol 26 (4) ◽  
pp. 347-354 ◽  
Author(s):  
Priscila H. Goncalves ◽  
Francine High ◽  
Paul Juniewicz ◽  
Gareth Shackleton ◽  
Jing Li ◽  
...  

2020 ◽  
Vol 112 (1) ◽  
pp. 331-338
Author(s):  
Kiyohiko Hatake ◽  
Takaaki Chou ◽  
Toshihiko Doi ◽  
Yasuhito Terui ◽  
Harumi Kato ◽  
...  

2009 ◽  
Author(s):  
Patricia LoRusso ◽  
Razelle Kurzrock ◽  
Amy Weise ◽  
Elisabeth Heath ◽  
Michel Drouin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document